Frenkel D, Katz O, Solomon B
Department of Molecular Microbiology and Biotechnology, The George S. Wise Faculty of Life Sciences, Tel-Aviv University, Ramat Aviv, Tel-Aviv 69978, Israel.
Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11455-9. doi: 10.1073/pnas.97.21.11455.
The epitope EFRH, corresponding to amino acids 3-6 within the human beta-amyloid peptide (AbetaP), acts as a regulatory site controlling both the formation and disaggregation process of the beta-amyloid fibrils (Abeta). Locking of this epitope by highly specific antibodies affects the dynamics of the entire AbetaP molecule, preventing self-aggregation as well as enabling resolubilization of already formed aggregates. Production of such antibodies by repeated injections of toxic human Abeta fibrils into transgenic mice suggests the feasibility of vaccination against Alzheimer's disease. Here, we report the development of an immunization procedure for the production of effective anti-aggregating beta-amyloid antibodies based on filamentous phages displaying the EFRH peptide as specific and nontoxic antigen. Effective autoimmune antibodies were obtained by EFRH phage administration in guinea pigs, which exhibit AbetaP identical to the human AbetaP region. Moreover, because of the high antigenicity of the phage, no adjuvant is required to obtain high affinity anti-aggregating IgG antibodies after a short immunization period of 3 weeks. Availability of such antibodies opens up possibilities for the development of an efficient and long-lasting vaccination for the prevention and treatment of Alzheimer's disease.
表位EFRH对应于人类β-淀粉样肽(AbetaP)内的第3至6个氨基酸,它作为一个调控位点,控制着β-淀粉样纤维(Abeta)的形成和解聚过程。高特异性抗体对该表位的锁定会影响整个AbetaP分子的动态变化,既能防止自我聚集,又能使已形成的聚集体重新溶解。通过向转基因小鼠反复注射有毒的人类Abeta纤维来产生此类抗体,这表明了针对阿尔茨海默病进行疫苗接种的可行性。在此,我们报告了一种免疫程序的开发,该程序基于展示EFRH肽作为特异性无毒抗原的丝状噬菌体来生产有效的抗聚集β-淀粉样抗体。通过向豚鼠施用EFRH噬菌体获得了有效的自身抗体,豚鼠体内的AbetaP与人AbetaP区域相同。此外,由于噬菌体具有高抗原性,在3周的短免疫期后,无需佐剂就能获得高亲和力的抗聚集IgG抗体。此类抗体的可得性为开发一种高效且持久的用于预防和治疗阿尔茨海默病的疫苗开辟了可能性。